Michael E. Ernst Pharm.D., FCCP, Michelle A. Fravel Pharm.D., FCCP
{"title":"Clinical pharmacy and patient safety: Have we reached a golden era?","authors":"Michael E. Ernst Pharm.D., FCCP, Michelle A. Fravel Pharm.D., FCCP","doi":"10.1002/jac5.2012","DOIUrl":"https://doi.org/10.1002/jac5.2012","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 8","pages":"742-743"},"PeriodicalIF":1.3,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141966884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Steven Theodore Johnson Pharm.D., Micheline Andel Goldwire Pharm.D., M.S., M.A., Maha Abdalla Pharm.D., Ph.D., Ashish Advani Pharm.D., Abdullah M. Alhammad Pharm.D., Keri C. Anderson Pharm.D., Allison Bernknopf Pharm.D., MSMI, Matthew L. Blommel Pharm.D., Rachel Brunner Pharm.D., JorDonna Frazier Pharm.D., Prit Gor B.S., Rena Gosser Pharm.D., Heather Ipema Pharm.D., Karen L. Kier Ph.D., M.Sc., FCCP, Audrey Kostrzewa Pharm.D., MPH, Daniel Majerczyk Pharm.D., Ed.M., FCCP, Radha Manian Ph.D., Erin Maxwell Pharm.D., Dianne May Pharm.D., FCCP, J. Russell May Pharm.D., Faria Munir Pharm.D., M.S., Ife Okafar Pharm.D., Jennifer Phillips Pharm.D., FCCP, Alia A. Poore Pharm.D., Maha Saad Pharm.D., Julie B. Sibbesen Pharm.D., Christine D. Sommer Pharm.D., M.A.
Pharmacists play a key role in helping to identify and combat the spread of medical misinformation. To do this effectively, pharmacists need to be equipped with skills and tools to respond to medical misinformation as it relates to patient care. The lack of peer-reviewed research on how to approach medical misinformation illustrates the need for specific strategies on how to identify, combat, and report medical misinformation. This article describes practical tactics pharmacists can use to teach learners the knowledge and skills necessary to reduce the spread of medical misinformation from various sources, including social media and artificial intelligence.
{"title":"Teaching learners to identify and reduce the spread of medical misinformation","authors":"Steven Theodore Johnson Pharm.D., Micheline Andel Goldwire Pharm.D., M.S., M.A., Maha Abdalla Pharm.D., Ph.D., Ashish Advani Pharm.D., Abdullah M. Alhammad Pharm.D., Keri C. Anderson Pharm.D., Allison Bernknopf Pharm.D., MSMI, Matthew L. Blommel Pharm.D., Rachel Brunner Pharm.D., JorDonna Frazier Pharm.D., Prit Gor B.S., Rena Gosser Pharm.D., Heather Ipema Pharm.D., Karen L. Kier Ph.D., M.Sc., FCCP, Audrey Kostrzewa Pharm.D., MPH, Daniel Majerczyk Pharm.D., Ed.M., FCCP, Radha Manian Ph.D., Erin Maxwell Pharm.D., Dianne May Pharm.D., FCCP, J. Russell May Pharm.D., Faria Munir Pharm.D., M.S., Ife Okafar Pharm.D., Jennifer Phillips Pharm.D., FCCP, Alia A. Poore Pharm.D., Maha Saad Pharm.D., Julie B. Sibbesen Pharm.D., Christine D. Sommer Pharm.D., M.A.","doi":"10.1002/jac5.2014","DOIUrl":"https://doi.org/10.1002/jac5.2014","url":null,"abstract":"<p>Pharmacists play a key role in helping to identify and combat the spread of medical misinformation. To do this effectively, pharmacists need to be equipped with skills and tools to respond to medical misinformation as it relates to patient care. The lack of peer-reviewed research on how to approach medical misinformation illustrates the need for specific strategies on how to identify, combat, and report medical misinformation. This article describes practical tactics pharmacists can use to teach learners the knowledge and skills necessary to reduce the spread of medical misinformation from various sources, including social media and artificial intelligence.</p>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 9","pages":"926-940"},"PeriodicalIF":1.3,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142170316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Integrating pharmacists into interdisciplinary care models is essential for achieving the Quintuple Aim in health care, which emphasizes improving patient outcomes, enhancing patient and provider experiences, reducing costs, and advancing health equity. Despite expanded scopes of practice that facilitate collaborative models, pharmacists often face significant barriers due to inconsistent and insufficient reimbursement for their clinical services. This review seeks to address these challenges by focusing on state-based legislation and regulations that establish payment parity or create pathways for reimbursing pharmacist clinical services. Through a narrative review, this article systematically compares different states' approaches to pharmacist reimbursement by examining affected payers, billable services, and other pertinent details. The ultimate goal is to propose model characteristics for states considering the enhancement or development of legislation and regulations to ensure equitable payment mechanisms for pharmacist services. By providing a comprehensive overview of existing models and identifying effective legislative characteristics, this review aims to inform and empower pharmacists and their advocates with a better understanding of reimbursement regulations and to inspire community-driven advocacy for equitable compensation, thus supporting the integration of pharmacists as essential health care providers.
{"title":"State of the union: A review of state-based laws and regulations supporting pharmacist payment for clinical services","authors":"Advancing Pharmacist Payment Parity Workgroup","doi":"10.1002/jac5.2008","DOIUrl":"10.1002/jac5.2008","url":null,"abstract":"<p>Integrating pharmacists into interdisciplinary care models is essential for achieving the Quintuple Aim in health care, which emphasizes improving patient outcomes, enhancing patient and provider experiences, reducing costs, and advancing health equity. Despite expanded scopes of practice that facilitate collaborative models, pharmacists often face significant barriers due to inconsistent and insufficient reimbursement for their clinical services. This review seeks to address these challenges by focusing on state-based legislation and regulations that establish payment parity or create pathways for reimbursing pharmacist clinical services. Through a narrative review, this article systematically compares different states' approaches to pharmacist reimbursement by examining affected payers, billable services, and other pertinent details. The ultimate goal is to propose model characteristics for states considering the enhancement or development of legislation and regulations to ensure equitable payment mechanisms for pharmacist services. By providing a comprehensive overview of existing models and identifying effective legislative characteristics, this review aims to inform and empower pharmacists and their advocates with a better understanding of reimbursement regulations and to inspire community-driven advocacy for equitable compensation, thus supporting the integration of pharmacists as essential health care providers.</p>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 9","pages":"908-925"},"PeriodicalIF":1.3,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141800607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lana Alhashimi Pharm.D., David J. Cordwin Pharm.D., Jessica Guidi M.D., Scott L. Hummel M.D., M.S., Todd M. Koelling M.D., Michael P. Dorsch Pharm.D., M.S.
Introduction
Guideline-directed medical therapy (GDMT) has significantly improved outcomes in patients with heart failure with reduced ejection fraction. However, GDMT prescribing remains suboptimal. The purpose of this study was to survey cardiologists, internists, and pharmacists on their approach to GDMT prescribing.
Methods
A survey containing 20 clinical vignettes of patients with heart failure with reduced ejection fraction was answered by 127 cardiologists, 68 internists, and 89 pharmacists. Each vignette presented options for adjusting GDMT. Responses were dichotomized to the answer of interest. A mixed-effect model was used to calculate the odds of changing GDMT between pharmacists and physicians.
Results
Pharmacists were more likely to make changes to GDMT compared with internists (92.1 vs. 82%; odds ratio [OR] 3.02 [1.50–6.06]; p = 0.002). In medically naïve patients, pharmacists were more likely to initiate beta-blockers than internists (45.4 vs. 32.0%; OR 2.19 [1.00–4.79], p = 0.049). Pharmacists were more likely than both internists and cardiologists to initiate mineralocorticoid receptor antagonists (34.4 vs. 11.5%; OR 4.95 [2.41–10.18]; p < 0.001 and 34.4 vs. 13.9%; OR 3.95 [2.16–7.21]; p < 0.001). Pharmacists were more likely than both internists and cardiologists to titrate beta-blockers (30.9 vs. 16.4%; OR 3.15 [1.92–5.19]; p < 0.001 and 30.9 vs. 22.0%; OR 1.88 [0.18–2.87]; p = 0.0030). Pharmacists were more likely than internists to titrate angiotensin receptor-neprilysin inhibitors (61.8 vs. 34.1%; OR 3.54 [1.50–8.39]; p = 0.004).
Conclusions
The survey results show pharmacists were more likely to make any adjustments to GDMT than internists and cardiologists. Pharmacists prefer adding spironolactone and titrating beta-blockers compared with cardiologists and internists. Compared with only internists, pharmacists were more likely to initiate beta-blockers and titrate the dose of angiotensin receptor-neprilysin inhibitor.
{"title":"Differences in the approach to guideline-directed medical therapy in patients with heart failure with reduced ejection fraction: A survey of cardiologists, internists, and pharmacists","authors":"Lana Alhashimi Pharm.D., David J. Cordwin Pharm.D., Jessica Guidi M.D., Scott L. Hummel M.D., M.S., Todd M. Koelling M.D., Michael P. Dorsch Pharm.D., M.S.","doi":"10.1002/jac5.2013","DOIUrl":"10.1002/jac5.2013","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Guideline-directed medical therapy (GDMT) has significantly improved outcomes in patients with heart failure with reduced ejection fraction. However, GDMT prescribing remains suboptimal. The purpose of this study was to survey cardiologists, internists, and pharmacists on their approach to GDMT prescribing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A survey containing 20 clinical vignettes of patients with heart failure with reduced ejection fraction was answered by 127 cardiologists, 68 internists, and 89 pharmacists. Each vignette presented options for adjusting GDMT. Responses were dichotomized to the answer of interest. A mixed-effect model was used to calculate the odds of changing GDMT between pharmacists and physicians.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Pharmacists were more likely to make changes to GDMT compared with internists (92.1 vs. 82%; odds ratio [OR] 3.02 [1.50–6.06]; <i>p</i> = 0.002). In medically naïve patients, pharmacists were more likely to initiate beta-blockers than internists (45.4 vs. 32.0%; OR 2.19 [1.00–4.79], <i>p</i> = 0.049). Pharmacists were more likely than both internists and cardiologists to initiate mineralocorticoid receptor antagonists (34.4 vs. 11.5%; OR 4.95 [2.41–10.18]; <i>p</i> < 0.001 and 34.4 vs. 13.9%; OR 3.95 [2.16–7.21]; <i>p</i> < 0.001). Pharmacists were more likely than both internists and cardiologists to titrate beta-blockers (30.9 vs. 16.4%; OR 3.15 [1.92–5.19]; <i>p</i> < 0.001 and 30.9 vs. 22.0%; OR 1.88 [0.18–2.87]; <i>p</i> = 0.0030). Pharmacists were more likely than internists to titrate angiotensin receptor-neprilysin inhibitors (61.8 vs. 34.1%; OR 3.54 [1.50–8.39]; <i>p</i> = 0.004).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The survey results show pharmacists were more likely to make any adjustments to GDMT than internists and cardiologists. Pharmacists prefer adding spironolactone and titrating beta-blockers compared with cardiologists and internists. Compared with only internists, pharmacists were more likely to initiate beta-blockers and titrate the dose of angiotensin receptor-neprilysin inhibitor.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 9","pages":"881-887"},"PeriodicalIF":1.3,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.2013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141810144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chi-Hua Lu Pharm.D., Edward M. Bednarczyk Pharm.D., FCCP
{"title":"Response to Comment on “Navigating obstacles: Perspectives of US pharmacy residency directors on non-US candidates for PGY-1 residencies: A survey-based research”","authors":"Chi-Hua Lu Pharm.D., Edward M. Bednarczyk Pharm.D., FCCP","doi":"10.1002/jac5.1992","DOIUrl":"https://doi.org/10.1002/jac5.1992","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 7","pages":"681"},"PeriodicalIF":1.3,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141583796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Christina Gutierrez Pharm.D., Rebecca Brady Pharm.D., Elizabeth O. Hand Pharm.D., Josefa Benedetti Pharm.D., Darrel W. Hughes Pharm.D., FCCP
{"title":"Comment on “Professional and career development needs of clinical pharmacists in settings outside academia”","authors":"G. Christina Gutierrez Pharm.D., Rebecca Brady Pharm.D., Elizabeth O. Hand Pharm.D., Josefa Benedetti Pharm.D., Darrel W. Hughes Pharm.D., FCCP","doi":"10.1002/jac5.1990","DOIUrl":"https://doi.org/10.1002/jac5.1990","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 7","pages":"677"},"PeriodicalIF":1.3,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141583989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Valerie Moore Pharm.D., Kirsten Ohler Pharm.D., FCCP
{"title":"Comment on “Factors associated with attaining a pharmacy residency interview: A scoping review”","authors":"Valerie Moore Pharm.D., Kirsten Ohler Pharm.D., FCCP","doi":"10.1002/jac5.1989","DOIUrl":"https://doi.org/10.1002/jac5.1989","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 7","pages":"678"},"PeriodicalIF":1.3,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141583884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Margaret Choye Pharm.D., Kristen H. Ohler Pharm.D., FCCP
{"title":"Comment on “Navigating obstacles: Perspectives of US pharmacy residency directors on non-US candidates for PGY-1 residencies: A survey-based research”","authors":"Margaret Choye Pharm.D., Kristen H. Ohler Pharm.D., FCCP","doi":"10.1002/jac5.1993","DOIUrl":"https://doi.org/10.1002/jac5.1993","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 7","pages":"680"},"PeriodicalIF":1.3,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141583795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Dual degree pharmacy practice faculty scholarship: Some answers but many more questions","authors":"B. Joseph Guglielmo Pharm.D.","doi":"10.1002/jac5.1984","DOIUrl":"https://doi.org/10.1002/jac5.1984","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 7","pages":"619-620"},"PeriodicalIF":1.3,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141584060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"2024 ACCP Virtual Poster Symposium May 21 - 22, 2024","authors":"","doi":"10.1002/jac5.1986","DOIUrl":"https://doi.org/10.1002/jac5.1986","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 7","pages":"682-737"},"PeriodicalIF":1.3,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141583817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号